Briacell Therapeutics Corp (BCTX)

• $0.66

  $0.73

  $0.73
  

  9.59%

  Downside

  Day's Volatility :9.59%

  Upside

  0.0%

  
• $0.52

  $7.18

  $0.73
  

  28.68%

  Downside

  52 Weeks Volatility :92.75%

  Upside

  89.83%

  

Returns

What analysts predicted

Upside of 2365.75%

• Lynwood Capital Management Inc.

  8.74%

• BMO Capital Markets Corp.

  0.73%

• Bank of Montreal

  0.73%

• Redmond Asset Management, LLC

  0.63%

• Onyx Bridge Wealth Group LLC

  0.27%

• Summit Trail Advisors, LLC

  0.19%

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.